ViroGates Appoints New Board Member To Speed Up Access To The United States Diagnostics Market John J. Reddington, DVM, PhD, COO of Cambridge Biomedical Inc. and former CEO of Sirtex Medical Inc., to join ViroGates’ non-executive board.
John J. Reddington, Chief Operation Officer of Cambridge Biomedical Inc., was appointed to the company’s board of directors, increasing the number of board members to 7. John R. Reddington currently serves as COO of Cambridge Biomedical Inc., a contract laboratory research organisation (CLIA) located in Boston, Ma., who supports the pharmaceutical, biopharmaceutical and Medical device industries with assay development and validation of biomarkers, companion diagnostic and specimen analysis. Since 2011, John J. Reddington has been on the board of Directors at Pathology Experts, an earlystage privately held consulting firm, who service the histopathology, toxicology and preclinical research needs of Life Sciences companies in Europe and North America.
Virogates has just received notification from the European Patent Office that Patent application 07858108.9 Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular disease will be granted. The Patent will be subject to national filing in the European countries, and will allow ViroGates protection of use of its suPARnostic® product range in the testing of healthy individuals to determine risk of development of cardiovascular disease, which is the leading cause of death worldwide. Furthermore ViroGates and Hvidovre Hospital have recently announced that suPARnostic has been implemented at the Danish Hospitals Acute Medical Ward.